Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
1(R)-1-acetamido-2-(3-carboxyphenyl)ethyl boronic acid is a synthetic small molecule and organoboron compound. It is structurally characterized by an acetamido group, a carboxy-substituted phenyl ring, and a boronic acid moiety. This compound has been studied primarily as an experimental inhibitor of β-lactamase enzymes, particularly TEM-type β-lactamases in bacteria. By mimicking the transition state of the enzyme's natural substrate, it acts as a competitive inhibitor at the active site of β-lactamase, potentially restoring the efficacy of β-lactam antibiotics against resistant bacterial strains[5][7]. The compound remains experimental with no approved clinical indications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 1(R)-1-acetamido-2-(3-carboxyphenyl)ethyl boronic acid.